8.43

2.93% +0.24

Outlook Therapeutics Inc (OTLK)

Overview News Price History Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is currently priced at $8.43, with a 24-hour trading volume of 120.16K. It has seen a +2.93% increased in the last 24 hours and a -2.88% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $8.14 pivot point. If it approaches the $8.66 resistance level, significant changes may occur.

Previous Close:

$8.19

Open:

$8.22

24h Volume:

120.16K

Market Cap:

$196.41M

Revenue:

Net Income/Loss:

$-51.50M

P/E Ratio:

-33.72

EPS:

-0.25

Net Cash Flow:

$-47.10M

1W Performance:

+3.18%

1M Performance:

-2.88%

6M Performance:

+1,479%

1Y Performance:

+680.56%

1D Range:

$8.135

$8.50

52W Range:

$0.2002

$12.85

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

609-619-3990

Address

7 Clarke Drive, Cranbury, NJ

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

OTLK's Discussions on Twitter

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Dow Dips 200 Points; Nike Shares Fall After Q3 Results

Benzinga

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire Inc.

Outlook Therapeutics Inc Stock (OTLK) Financials Data

Outlook Therapeutics Inc (OTLK) Net Income 2024

OTLK net income (TTM) was -$51.50 million for the quarter ending December 31, 2023, a +26.69% increase year-over-year.

Outlook Therapeutics Inc (OTLK) Cash Flow 2024

OTLK recorded a free cash flow (TTM) of -$47.10 million for the quarter ending December 31, 2023, a +13.71% increase year-over-year.

Outlook Therapeutics Inc (OTLK) Earnings per Share 2024

OTLK earnings per share (TTM) was -$4.00 for the quarter ending December 31, 2023, a +35.48% growth year-over-year.

Outlook Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its lead clinical program is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in Phase I clinical trial for the treatment of wet age related macular degeneration. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.